Thymopentin treatment in genital warts of long duration.
The immunomodulatory effect of thymopentin as therapy in genital warts of long duration and the proliferative responses of the patient's peripheral blood mononuclear cells were investigated in this pilot study. The observations in 6 patients suggest that subcutaneous injections of thymopentin (50 mg) beneficially influence the systems of therapy-resistant genital warts. The small number of patients and controls used in the assessment of the proliferation responses allows only a descriptive analysis of the results, but definitive trends can be observed in the Con A- and PHA-induced proliferation tests. These clinical observations, the theoretical considerations, and the low rate of side effects of thymopentin reported also by other investigators all emphasize the importance of further well-controlled double-blind studies on the treatment of genital warts with thymopentin.